Pamela Garner-Jones, Christie patient

Pamela Garner-Jones from Cheshire was diagnosed with cervical cancer in 2021. After receiving chemotherapy treatment, her cancer was initially kept under control. In 2024, Pamela’s cancer came back, the chemotherapy stopped working and further treatment options were limited.

After this devastating news, Pamela joined the TARGET National study. The Christie Charity is helping to fund this groundbreaking, UK-wide cancer study which has a focus on personalised medicine.

When Pamela joined TARGET National, she was given a simple blood test and was matched with a drug trial called DETERMINE, which she started in 2024.

TARGET National has been a lifeline for Pamela. Her tumours have shrunk by almost 2-thirds in size and importantly, she is no longer suffering from any symptoms.

The study has currently recruited nearly 4,000 patients, with 490 of these at The Christie. Ultimately the study aims to collect enough data to help support an NHS application to introduce this test routinely for cancer patients.

I’m all in favour of these studies and trials. My attitude is unless you try these things you will never know. I realise some people are nervous about going on a clinical trial, but I think it is an opportunity to help other people in the future as well as myself.
Pamela Garner-Jones, Christie patient

Donate to The Christie Charity’s Clear appeal today and help fund the research that brings the next breakthrough into focus.

A photo of Christie TARGET trial patient Pamela Garner Jones.